Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 2, 2026Drugs & Therapy Perspectives

DOACs likely outperform warfarin in older AF patients, but frail patients require individualized care.

View Full Paper
Ask AI
Bookmark
Share

Why the study?

How should frailty and comorbidities influence the choice between DOACs and warfarin in older patients with atrial fibrillation?

Comparison

DOACs vs warfarin

Key result

Direct oral anticoagulants likely offer greater treatment benefits than warfarin for older patients with atrial fibrillation, though individualized approaches are needed for frail patients.

Authors

AMAisling McGuigan

Discussion

Loading...

Member takes

Overview

Supports individualized DOAC use in older AF patients; leaves open frailty-specific prospective trials.

Key Points

  • To assess the effectiveness of anticoagulants in older patients with atrial fibrillation, considering frailty and comorbidities.
  • Evaluated the use of direct oral anticoagulants (DOACs) vs warfarin in older patients with atrial fibrillation.
  • Considered patient factors like frailty, chronic kidney disease, and history of bleeding when determining treatment options.
  • DOACs show greater treatment benefits compared to warfarin in older patients with atrial fibrillation.
  • Patient subgroups with frailty and comorbidities still retain benefits from DOACs despite increased bleeding risks.

Structured PICO

How should frailty and comorbidities influence the choice between DOACs and warfarin in older patients with atrial fibrillation?

P
Population
Older patients with atrial fibrillation, including those with advanced age, frailty, increased risk of falling, chronic kidney disease, or a history of bleeding
I
Intervention
Direct oral anticoagulants (DOACs)
C
Comparator
Warfarin (vitamin K antagonist)
O
Outcome
Risk of stroke and major bleeding

DOACs are generally preferred over warfarin in older patients with AF, but individualized assessment is crucial for those with frailty or significant comorbidities.

Cite This Study

Aisling McGuigan (2026) conducted a review in Atrial fibrillation. Direct oral anticoagulants (DOACs) vs. Warfarin was evaluated. Direct oral anticoagulants likely offer greater treatment benefits than warfarin for older patients with atrial fibrillation, though individualized approaches are needed for frail patients.

synapsesocial.com/papers/6a4602ec9ed1343031311b72https://doi.org/10.1007/s40267-026-01248-7
View Full Paper
Ask AI
Bookmark
Share